COMMUNIQUÉS West-GlobeNewswire

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07/05/2025
REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07/05/2025
Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of [...]
Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results at ARVO 2025
07/05/2025
Innovative antisense therapy blocking production of TGF-β2 shows promise in reducing retinal fibrosis and improving outcomes in patients with wet AMD and DME Gräfelfing, Germany, May 7 th , 2025 – Isarna Therapeutics [...]
European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease
07/05/2025
TREMFYA ® (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remission a and endoscopic response b at Week 12 [...]
Oculis to Present at Upcoming May Investor Conferences
07/05/2025
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Oculis to Present at Upcoming May Investor Conferences
07/05/2025
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Prime Biome Reviews Fixed What Doctors Couldn’t – In Just Weeks! A Reality Based, Self Trial, Facts and Figure Which Revealed the Truth!
07/05/2025
St. Petersburg, Florida, May 07, 2025 (GLOBE NEWSWIRE) -- as per studies a person's complete health depends on gut and skin health, especially in our fast-paced environment. People are most concerned about their stomach [...]
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
07/05/2025
WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is [...]
Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL
07/05/2025
Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006) Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrence [...]
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
07/05/2025
Freiburg, May 7 th , 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. [...]
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
07/05/2025
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial [...]
Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
07/05/2025
BJT-188 demonstrated liver-specific potency with minimal exposure to other tissues The data are being presented at the European Association for the Study of the Liver (EASL) Congress 2025 REDWOOD CITY, Calif., May 07, [...]
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
07/05/2025
Additional late-breaking data suggests up to twice as many patients treated with IQIRVO ® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatment IQIRVO dual PPAR α / δ [...]
De nouvelles données issues d’analyses exploratoires soulignent l’impact d’IQIRVO® (élafibranor) sur la fatigue et mettent en lumière son mécanisme d’action sur l’inflammation et les symptômes associés à la cholangite biliaire primitive
07/05/2025
D’autres données nouvelles suggèrent que jusqu’à deux fois plus de patients traités avec IQIRVO ® ont constaté une amélioration cliniquement significative de la fatigue par rapport au placebo après 52 semaines de [...]
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
07/05/2025
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher Edinburgh, UK, 7 May 2025 - Trogenix Ltd (“Trogenix”), a pioneering [...]
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
07/05/2025
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% at constant exchange rates (CER) to DKK 38.8 billion. Sales in US Operations [...]
CROSSJECT provides updates on the EUA filing of ZEPIZURE®
07/05/2025
Press Release CROSSJECT provides updates on the EUA filing of ZEPIZURE® CROSSJECT and its EUROFINS CDMO partner successfully completed the aseptic filling of all ZEPIZURE® registration batches and anticipate the [...]
CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE®
07/05/2025
Communiqué de presse CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE® CROSSJECT et son partenaire EUROFINS ont achevé avec succès le remplissage aseptique de tous les lots [...]
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
07/05/2025
Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024 Cash and cash equivalents of €153.0 million at end of March 2025 Further clinical and regulatory progress 2025 financial outlook [...]

Pages